1. Morton L. Kern. Cardiac Catheterization Handbook, Saunder. 2013
2. Grossman Cardiac Catheterization, Angiography, and Intervention by Donald S.Baim. 2012
3. Louise C, Philipp L, et al. Percutaneous pulmonary valvuloplasty; Percutaneous interventional cardiovascular medicine- The PCR- EAPCI textbook: volume III, part 3; 141-150
4. ESC Guidelines for the management of Grow-up Congenital disease (new version 2010): The Task Force on the Management of Grow-up Congenital Heart Disease of the European Society of Cardiology. Eur Heart J. 2010
5. Cardi-O-Fix duct occluder versus amplatzer duct occluder for closure of patent ductus arteriosus: Short-term and mid-term results. Celebı A, Halil Demır I, Sarıtaş T, Dedeoğlu R, Kemal Yucel I, Demir F, Erdem A. Catheter Cardiovasc Interv. 2013 Apr 16.
6. Transcatheter closure of patent ductus arteriosus with the new Amplatzer Duct OccluderII. Ji W, Li F, Gao W, Yu ZQ, Huang MR, Fu LJ, Guo Y, Zhao PJ, Liu TL, Zhang YQ, Chen YW. Zhonghua Er Ke Za Zhi. 2013
7. Granja MA, Trentacoste L, Rivarola M, et al (2013). Multicenter Nit-Occlud® PDA-R Patent Ductus Arteriosus Occlusion Device Trial Initial and Six-Month Results.. Catheter Cardiovasc Interv. 2013
8. Transcatheter closure of persistent ductus arteriosus in adults. Bentham JR, Thomson JD, Gibbs JL. J Interv Cardiol. 2012 Oct;25(5):501-4.
9. Comparison of the efficacy of different-sized Amplatzer duct occluders (I, II, and II AS) in children weighing less than 10 kg. Baspinar O, Irdem A, Sivasli E, Sahin DA, Kilinc M. Pediatr Cardiol. 2013 Jan;34(1):88-94.
10. Meier B, Palacios I, Windecker S, et al (November 2003). “Transcatheter left atrial appendage occlusion with Amplatzer devices to obviate anticoagulation in patients with atrial fibrillation”. Catheter Cardiovasc Interv 60 (3): 417–22.
11. Crystal E, Lamy A, Connolly SJ, et al (January 2003). “Left Atrial Appendage Occlusion Study (LAAOS): a randomized clinical trial of left atrial appendage occlusion during routine coronary artery bypass graft surgery for long-term stroke prevention”. Am. Heart J. 145 (1): 174–8.
12. Healey JS, Crystal E, Lamy A, et al (August 2005). “Left Atrial Appendage Occlusion Study (LAAOS): results of a randomized controlled pilot study of left atrial appendage occlusion during coronary bypass surgery in patients at risk for stroke”. Am. Heart J. 150 (2): 288–93.
13. Di Mario C et al. (2007). European perspective in the recanalisation of Chronic Total Occlusions (CTO): consensus document from the EuroCTO Club. EuroInterv 3: 30–43.
14. Transcatheter closure of perimembranous ventricular septal defect with the amplatzer membranous VSD occluder 2: Initial world experience and one-year follow-up. Tzikas A, Ibrahim R, Velasco-Sanchez D, Freixa X, Alburquenque M, Khairy P, Bass JL, Ramirez J, Aguirre D, Miro J. Catheter Cardiovasc Interv. 2013 May 22.
15. Transcatheter closure of secundum atrial septal defect. Shimpo H, Hojo R, Ryo M, Konuma T, Tempaku H. Gen Thorac Cardiovasc Surg. 2013 Jun 1
16. Bonow RO, et al. (2008). 2008 Focused update incorporated into the ACC/AHA 2006 Guidelines for the management of patients with valvular heart disease: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing committee to revise the 1998 Guidelines for the management of patients with valvular heart disease). Circulation, 118(15): e523-e661.
17. Meier B, Palacios I, Windecker S, et al (November 2003). “Transcatheter left atrial appendage occlusion with Amplatzer devices to obviate anticoagulation in patients with atrial fibrillation”. Catheter Cardiovasc Interv 60 (3): 417–22.